LITS · XBRL financial data
Lite Strategy financial statements, every fiscal year
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (LITS's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Jun 30, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 34,796 | 40,697 | 48,816 | 65,297 | 0 | — |
| Cost of goods and services sold | 1,408 | 0 | — | — | — | — |
| Research and development | 69,398 | 85,641 | 52,450 | 16,561 | 3,923 | 122 |
| General and administrative | 24,414 | 30,540 | 33,130 | 23,295 | 13,532 | 12,047 |
| Operating income (loss) | (60,424) | (75,484) | (36,764) | 14,542 | (17,455) | (66,577) |
| Other income (expense) | 486 | (6) | (22) | (41) | (16) | 0 |
| Income tax expense (benefit) | 8 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (41,314) | (54,454) | (32,000) | 17,778 | (15,945) | (71,150) |
| Earnings per share, basic USD per share | (0.37) | (0.44) | (4.78) | 2.67 | (2.39) | (2.06) |
| Earnings per share, diluted USD per share | (0.60) | (0.50) | (4.78) | 2.67 | (2.39) | (2.06) |
| Weighted average shares, basic thousands of shares | 112,527 | 124,473 | 6,663 | 6,663 | 6,663 | 34,559 |
| Weighted average shares, diluted thousands of shares | 114,481 | 125,142 | 6,663 | 6,663 | 6,663 | 34,559 |
- † Share count changed about 1/20 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (LITS's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Jun 30, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8,543 | 15,740 | 16,906 | 3,705 | 18,011 | 5,706 |
| Short-term investments | 144,883 | 137,512 | 83,787 | 34,640 | 0 | — |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 | — |
| Prepaid and other current assets | 3,809 | 3,830 | 6,750 | 2,424 | 274 | 435 |
| Total current assets | 164,817 | 167,126 | 107,528 | 40,769 | 18,285 | 6,141 |
| Property and equipment, net | 1,507 | 1,660 | 1,309 | 392 | 0 | — |
| Right-of-use asset | 7,774 | 9,054 | 11,972 | 214 | 0 | — |
| Total assets | 174,098 | 177,840 | 120,809 | 41,375 | 18,285 | 42,692 |
| Accounts payable | 6,355 | 7,918 | 6,134 | 3,168 | 176 | 261 |
| Accrued liabilities | 8,402 | 10,820 | 12,461 | 5,187 | 1,178 | 808 |
| Total current liabilities | 20,211 | 24,443 | 20,340 | 8,355 | 1,354 | 1,069 |
| Lease liability, non-current | 7,370 | 8,771 | 11,300 | 0 | — | — |
| Total liabilities | 124,632 | 125,427 | 96,185 | 8,355 | 1,354 | 1,069 |
| Accumulated deficit | (319,705) | (374,159) | (405,997) | (388,219) | (404,164) | (475,314) |
| Total stockholders' equity | 49,466 | 52,413 | 24,624 | 33,020 | 16,931 | 41,623 |
| Total liabilities and equity | 174,098 | 177,840 | 120,809 | 41,375 | 18,285 | 42,692 |
| Common shares outstanding (cover page) thousands of shares | 112,678 | 133,261 | 6,663 | 6,663 | 35,655 | 30,407 |
- † Share count changed about 1/20 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (LITS's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Jun 30, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (41,314) | (54,454) | (32,000) | 17,778 | (15,945) | (71,150) |
| Stock-based compensation | 10,245 | 8,350 | 3,589 | 2,278 | (144) | 1,288 |
| Depreciation and amortization | 285 | 326 | 386 | 383 | 368 | 0 |
| Net cash from operating activities | (31,964) | (48,746) | (52,484) | (50,473) | (20,844) | (9,121) |
| Purchases of property and equipment | 708 | 479 | 35 | 7 | 0 | — |
| Net cash from investing activities | 24,708 | 6,892 | 53,690 | 49,140 | 35,150 | (95,107) |
| Proceeds from issuing common stock | 3,200 | 52,325 | 0 | — | 0 | 4,628 |
| Share repurchases | — | — | — | — | 0 | 4,895 |
| Dividends paid | — | — | 0 | 11,660 | 0 | — |
| Net cash from financing activities | 3,468 | 49,051 | (40) | (11,868) | 0 | 91,923 |
- † Share count changed about 1/20 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Lite Strategy | 5,706 | not reported | (1,164)* | 30.4M | 4.9 quarters | 10-KJun 30, 2026 |
| Actinium Pharmaceuticals | 36,473 | 35,000 | (5,179)* | 31.4M | 7.0 quarters | 10-QJun 30, 2026 |
| Fortress Biotech | 196,576 | 18,718 | (59,277)* | 33.3M | 3.3 quarters | 10-QJun 30, 2026 |
| Actuate Therapeutics | 4,426 | not reported | (4,405)* | 24.0M | 1.0 quarters | 10-QJun 30, 2026 |
| Acumen Pharmaceuticals | 53,075 | not reported | (26,653)* | 72.3M | 3.4 quarters | 10-QSep 30, 2026 |
| Opus Genetics | 88,812 | 755 | (11,950)* | 83.2M | 7.4 quarters | 10-QJun 30, 2026 |
| CervoMed | 22,463 | 0 | (6,918)* | 15.1M | 3.6 quarters | 10-QJun 30, 2026 |
| Precision Biosciences | 81,698 | 0 | (15,132)* | 27.9M | 6.1 quarters | 10-QSep 30, 2026 |
| Atara Biotherapeutics | 3,221 | 630 | (3,338)* | 10.0M | 3.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.